SBIR/STTR Research Award
Multiplexed Nucleic Acid Assays
Award amount
$1,451,670Program and phase
SBIR · Phase IIAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PROGNOSYS BIOSCIENCES, INC.
- Proposal award date
- 2014-09-10
- Contract end date
- 2016-08-31
- UEI
- Not reported
- Solicitation number
- PA13-088
- Topic code
- 100
Research abstract
DESCRIPTION provided by applicant New technologies are needed to enable the multiplexed analysis of gene expression in many samples in parallel This would enable the generation of high resolution maps of gene expression of the mammalian brain as well as other complex tissues This proposal aims to develop novel technology to enable applications of this type It is suited to analyzing complex and dynamic biological systems including regulatory and communication systems that operate at the cellular and multicellular level PUBLIC HEALTH RELEVANCE We are developing technology to enable a deeper understanding of how the genetic blueprint is used to make and regulate the mammalian brain and other complex tissues The ultimate aim is to provide technology that enables new insights into how complex biological systems work and how this is altered in disease This understanding can be translated into diagnostic and prognostic assays preventative strategies and therapeutics
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing